PureTech Health plc

Equities

PRTC

GB00BY2Z0H74

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:12 2024-06-27 EDT 5-day change 1st Jan Change
187.8 GBX 0.00% Intraday chart for PureTech Health plc -12.65% -3.30%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
PureTech Health Buys Back $100 Million of Shares MT
EARNINGS AND TRADING: PureTech seals tender offer; HL bid questioned AN
Tranche Update on PureTech Health plc's Equity Buyback Plan announced on March 19, 2024. CI
PureTech Health to Buy Back $100 Million Shares Under Tender Offer MT
PureTech Health Names Raju Kucherlapati as Chair MT
PureTech Health plc Appoints Raju Kucherlapati as Chair of Board of Directors CI
PureTech Health plc's Equity BUyback announced on March 19, 2024, has closed with 31,540,670 shares, representing 11.6% for $100 million. CI
PureTech's Ankili to be acquired by Virtual Therapeutics AN
PureTech Health's Akili, Virtual Therapeutics Sign Merger Deal to Launch Digital Health Company MT
PureTech-founded Vedanta begins trials for VE303 colonic bacteria drug AN
PureTech Health Opens $100 Million Buyback Program MT
PureTech Health Launches $100 Million Share Repurchase MT
PureTech Health launches USD100 million buyback programme AN
EARNINGS AND TRADING: Asiamet Resources declares special dividend AN
EARNINGS AND TRADING: Asiamet Resources declares special dividend AN
Seaport Therapeutics Announces Board of Directors Changes and Makes Key Executive Appointments CI
Tranche Update on PureTech Health plc's Equity Buyback Plan announced on May 5, 2022. CI
Tranche Update on PureTech Health plc's Equity Buyback Plan announced on May 5, 2022. CI
Tranche Update on PureTech Health plc's Equity Buyback Plan announced on May 5, 2022. CI
Transcript : PureTech Health plc, 2023 Earnings Call, Apr 25, 2024
PureTech touts "momentum" as grants shrivel but annual loss narrows AN
Miner Anglo American reviews takeover bid from rival BHP AN
Miner Anglo American eyes rival BHP takeover AN
Correction: Earnings Flash (PRTC.L) PURETECH HEALTH Posts FY23 Loss $-0.24 MT
Earnings Flash (PRTC.L) PURETECH HEALTH Reports FY23 Revenue $3.3M MT
Chart PureTech Health plc
More charts
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.371 USD
Average target price
7.967 USD
Spread / Average Target
+236.08%
Consensus
  1. Stock Market
  2. Equities
  3. PRTC Stock
  4. News PureTech Health plc
  5. PureTech Health Names Raju Kucherlapati as Chair